Brief: Everest Medicines Says FY Loss Attributable RMB247.3 Mln
31/03/2023 24:00
March 31 (Reuters) - Everest Medicines Ltd 1952.HK :
* FY LOSS ATTRIBUTABLE RMB247.3 MILLION VERSUS LOSS OF
RMB1.01
BILLION
* FY REVENUE INCREASED BY RMB12.7 MLN TO RMB12.8 MLN
Source text for Eikon: ID:nHKSb0Bs0W
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region